Literature DB >> 11742902

COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer.

Y Sekine1, K A Kesler, M Behnia, J Brooks-Brunn, E Sekine, J W Brown.   

Abstract

PURPOSE: This study investigated the association of COPD and postoperative cardiac arrhythmias, specifically supraventricular tachycardia (SVT), as well as mortality in patients undergoing pulmonary resection for non-small cell lung cancer (NSCLC).
METHODS: A retrospective chart review of 244 patients who had undergone lung resection for NSCLC at Indiana University Hospital between 1992 and 1997 was undertaken. COPD, which was defined as an FEV(1) of < or = 70% predicted and an FEV(1)/FVC ratio of < or = 70% based on the results of a preoperative pulmonary function test (PFT), was diagnosed in 78 of the 244 patients (COPD group). In the remaining 166 patients, the results of preoperative PFTs did not meet these criteria (non-COPD group). Both groups were otherwise well-matched with respect to multiple variables, including age, comorbid conditions, extent of pulmonary resection, and final pathologic stage. The incidence of cardiac arrhythmias and operative mortality were compared between the two groups using univariate and multivariate analysis.
RESULTS: Seventy-six patients (31.9%) experienced new onsets of postoperative SVT, with 58 of these patients (76.3%) demonstrating atrial fibrillation. The COPD group had a 58.7% incidence of SVT (n = 44) compared to a 27.0% incidence (n = 44) in the non-COPD group (p < 0.0 0 1). Moreover, following initial digoxin therapy, the COPD group required more second-line antiarrhythmic therapy than did the non-COPD group (66.7% vs 37.8%, respectively; p = 0.0 03). Overall, there were 16 operative deaths (6.6%), and the mortality rate was significantly higher in the COPD group (14.1%) than in the non-COPD group (3.0%; p = 0.0 04). Patients who developed SVT had a significantly longer hospital course than did patients who did not (p < 0.0001). Thirteen of the 16 patients who died experienced SVT; however, SVT was not an independent risk factor for death. Finally, of the 19 variables evaluated, major resection (ie, pneumonectomy and bilobectomy) and COPD were identified as independent risk factors for the development of cardiac arrhythmias (p = 0.0 033 and p = 0.0 009, respectively).
CONCLUSION: Patients with COPD, as defined by the results of preoperative PFTs, are at significantly higher risk for SVT, and in particular SVT refractory to digoxin, following pulmonary resection for NSCLC. Although SVT was not an independent risk factor for death, a significantly longer hospitalization was observed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11742902     DOI: 10.1378/chest.120.6.1783

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  30 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  Efficacy of perioperative administration of long-acting bronchodilator on postoperative pulmonary function and quality of life in lung cancer patients with chronic obstructive pulmonary disease. Preliminary results of a randomized control study.

Authors:  Hidemi Suzuki; Yasuo Sekine; Shigetoshi Yoshida; Makoto Suzuki; Kiyoshi Shibuya; Yuichi Takiguchi; Koichiro Tatsumi; Ichiro Yoshino
Journal:  Surg Today       Date:  2010-09-25       Impact factor: 2.549

3.  Timeliness of Treatment Initiation and Associated Survival Following Diagnosis of Non-Small-Cell Lung Cancer in South Carolina.

Authors:  Jarrod T Bullard; Jan M Eberth; Amanda K Arrington; Swann A Adams; Xi Cheng; Ramzi G Salloum
Journal:  South Med J       Date:  2017-02       Impact factor: 0.954

4.  Association of thoracic epidural analgesia with risk of atrial arrhythmias after pulmonary resection: a retrospective cohort study.

Authors:  Ryu Komatsu; Natalya Makarova; Jarrod E Dalton; Zhuo Sun; Dennis Chang; Radhika Grandhe; Roshni Sreedharan; Karine De Oliveira Dias; Rakhi Pal; Allen Bashour; Sudish C Murthy; Alparslan Turan
Journal:  J Anesth       Date:  2014-06-24       Impact factor: 2.078

Review 5.  [Consequences of pneumonectomy in the early and late phases].

Authors:  R A Hatz; L V Klotz
Journal:  Chirurg       Date:  2013-06       Impact factor: 0.955

6.  Postoperative atrial fibrillation is less frequent in pulmonary segmentectomy compared with lobectomy.

Authors:  Takuya Ueda; Kenji Suzuki; Takeshi Matsunaga; Kazuya Takamochi; Shiaki Oh
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-11-13

Review 7.  Risk factors predictive of atrial fibrillation after lung cancer surgery.

Authors:  Takekazu Iwata; Kaoru Nagato; Takahiro Nakajima; Hidemi Suzuki; Shigetoshi Yoshida; Ichiro Yoshino
Journal:  Surg Today       Date:  2015-10-15       Impact factor: 2.549

8.  Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery.

Authors:  Takashi Makino; Hajime Otsuka; Yoshinobu Hata; Satoshi Koezuka; Yoko Azuma; Kazutoshi Isobe; Keishi Sugino; Satoru Ebihara; Sakae Homma; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2018-03-26

9.  Thoracoscopic minimally invasive surgery for non-small cell lung cancer in patients with chronic obstructive pulmonary disease.

Authors:  Fei Cui; Jun Liu; Wenlong Shao; Jianxing He
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

10.  The impact of chronic obstructive pulmonary disease and obesity on length of stay and cost of spine surgery.

Authors:  M Sami Walid; Nadezhda V Zaytseva
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.